Table 2.
Clinical course and outcome according to coagulation status: Group I (low anticoagulation status) included patients with both INR below 2.0 and aPTT ratio below 1.50; Group II (adequate anticoagulation status) included patients with either INR ≥ 2.0 or aPTT ratio ≥ 1.50
| Overall (n = 38) | Coagulation status at the time of event | Coagulation status two weeks prior of event | |||||
|---|---|---|---|---|---|---|---|
| N (%) | Group I (n = 12) | Group II (n = 26) | p | Group I (n = 8) | Group II (n = 30) | p | |
| Complications | |||||||
| Tamponade | 6 (16 %) | 0 | 6 (23 %) | .15 | 1 (13 %) | 5 (17 %) | .99 |
| Rethoracothomy | 7 (18 %) | 0 | 7 (27 %) | .07 | 1 (13 %) | 6 (20 %) | .99 |
| Infection | 9 (24 %) | 2 (17 %) | 7 (27 %) | .69 | 2 (25 %) | 7 (23 %) | .99 |
| GI bleeding | 2 (5 %) | 0 | 2 (8 %) | .99 | 0 | 2 (7 %) | .99 |
| RV failure | 8 (21 %) | 2 (17 %) | 6 (23 %) | .99 | 2 (25 %) | 6 (20 %) | .99 |
| AKI | 2 (5 %) | 1 (8 %) | 1 (4 %) | .54 | 1 (13 %) | 1 (3 %) | .38 |
| Median duration of follow-up in days (Q1-Q3) | 275 (75–522) | 299 | 242 | .94 | 314 | 254 | .96 |
| Median duration of LVAD support in days (Q1-Q3) | 279 (134–540) | 321 | 279 | .96 | 314 | 279 | .97 |
| Death before transplant | 4 (11 %) | 1 (8 %) | 3 (12 %) | .99 | 1 (13 %) | 3 (10 %) | .99 |
| Transplanted and alive | 9 (24 %) | 2 (17 %) | 7 (27 %) | .69 | 1 (13 %) | 8 (27 %) | .65 |
| Transplanted and deceased | 1 (3 %) | 0 | 1 (4 %) | .99 | 0 | 1 (3 %) | .99 |
| Weaned from LVAD | 3 (8 %) | 0 | 3 (12 %) | .54 | 1 (13 %) | 2 (7 %) | .99 |
| On-going LVAD support | 21 (55 %) | 9 (75 %) | 12 (46 %) | .16 | 5 (63 %) | 16 (53 %) | .71 |
| Thromboembolic stroke | 6 (16 %) | 2 (17 %) | 4 (15 %) | .99 | 0 (0 %) | 6 (20 %) | <.001 |
| Stroke rate during LVAD support (event/patient/year) | .160 | .169 | .156 | .99 | - | .173 | <.001 |